{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true},"limitationsAndCaveats":{"description":"Primary analysis was performed two years early as per IDMC recommendation and the exploratory analysis of final DFS data at the prespecified maturity of approx. 50% was done in 2022. After the final DFS data analysis and until the final OS analysis, only limited data were collected: subsequent anti-cancer treatment, survival status and limited safety data. The AZ7550 metabolite samples were not analyzed after Mar 2019, so the ratio of metabolite to AZD9291 was not available for calculation."},"pointOfContact":{"email":"ClinicalTrialTransparency@astrazeneca.com","organization":"AstraZeneca AB","phone":"+447920183730","title":"Global Clinical Leader"}}